Robotic-Assisted Surgery: Taking MIS By Storm

Robotically assisted surgical devices are one of the hottest and fastest growing segments in the market for minimally invasive surgery (MIS) products, with a global market opportunity projected to reach more than $10 billion by 2021. A growing number of competitors hope to capture share and further expand the market by targeting key procedures and geographies with next generation robotic surgery systems and robotic-like technologies designed to improve outcomes and enable more complex procedures to be performed via an MIS approach.

In the market for minimally invasive surgery (MIS) products, one of the hottest and fastest growing segments is robotically assisted surgical devices (RASD). In the last 15 years, Intuitive Surgical Inc., the market leader in RASD for soft tissue applications, has steadily increased penetration into MIS and demonstrated that robotic-assisted surgery is not just a gimmick or niche market, but a multibillion dollar global market opportunity that is projected to reach more than $10 billion by 2021.

In 2015 alone, Intuitive reported $2.38 billion in revenues and 652,000 procedures performed with its da Vinci Surgical System, up 12% and 14% respectively from 2014. Given the company's success,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.